ETheRNA was founded in January 2013 out of the VUB Laboratory for Molecular and Cellular Therapy (LMCT). Headed by Prof. Kris Thielemans together with Prof. Bart Neyns, LMCT has discovered and developed TriMix. This mRNA-based technology focuses on enhancing and modulating cells connected to the human immune response to cancer and infectious diseases.
“ETheRNA has the potential to transform the future of cancer treatment."
After showing a convincing set of preclinical and clinical data in, eTheRNA has succeeded in raising 24 million euro of proceeds, representing one of the biggest financings in Europe over the past year for an early-stage biotechnology company. These resources enable eTheRNA to conduct necessary further clinical studies with an off-the-shelf injectable mRNA-product.